Cite
HARVARD Citation
Harvey, C. et al. (n.d.). Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Journal for immunotherapy of cancer. p. . [Online].